Sarepta Therapeutics, Inc. (SRPT) |
|
127.41 -0.97 (-0.76%)
|
03-24 12:27 |
|
Open: |
128.97 |
Pre. Close: |
128.38 |
|
High:
|
130.38 |
Low:
|
126.99 |
|
Volume:
|
333,721 |
Market Cap:
|
11,210(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 12:04:33 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 167.62 One year: 186.69 |
| Support: |
Support1: 117.11 Support2: 97.43 |
| Resistance: |
Resistance1: 143.51 Resistance2: 159.83 |
| Pivot: |
140.68  |
| Moving Average: |
MA(5): 129.55 MA(20): 140.23
MA(100): 124.19 MA(250): 103.9 |
| MACD: |
MACD(12,26): -0.3 Signal(9): 2.4 |
| Stochastic oscillator: |
%K(14,3): 26.4 %D(3): 29 |
| RSI: |
RSI(14): 43.5 |
| 52-week: |
High: 159.83 Low: 61.27 |
| Average Vol(K): |
3-Month: 1,388 (K) 10-Days: 2,017 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SRPT ] has closed above bottom band by 20.2%. Bollinger Bands are 109.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
131.26 - 132.33 |
132.33 - 133.05 |
|
Low:
|
123.49 - 124.65 |
124.65 - 125.43 |
|
Close:
|
126.84 - 128.66 |
128.66 - 129.88 |
|
Company Description |
|
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Thu, 23 Mar 2023
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average ... - MarketBeat
Tue, 21 Mar 2023
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation - EIN News
Tue, 21 Mar 2023
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ... - Business Wire
Tue, 21 Mar 2023
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock? - Yahoo Life
Sun, 19 Mar 2023
SRPT EQUITY ALERT: ROSEN, A HIGHLY RECOGNIZED LAW ... - GlobeNewswire
Fri, 17 Mar 2023
Sarepta slides as FDA about-turn on panel clouds gene therapy ... - Reuters
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
88 (M) |
| Shares Float |
84 (M) |
|
% Held by Insiders
|
4.4 (%) |
|
% Held by Institutions
|
89.5 (%) |
|
Shares Short
|
6,720 (K) |
|
Shares Short P.Month
|
6,840 (K) |
Stock Financials |
|
EPS
|
-7.12 |
|
EPS Est Next Qtl
|
-0.38 |
|
EPS Est This Year
|
-1.13 |
|
EPS Est Next Year
|
-1 |
|
Book Value (p.s.)
|
9.6 |
|
Profit Margin (%)
|
-81.8 |
|
Operating Margin (%)
|
-61.1 |
|
Return on Assets (ttm)
|
-11.5 |
|
Return on Equity (ttm)
|
-159.2 |
|
Qtrly Rev. Growth
|
21.6 |
|
Gross Profit (p.s.)
|
-1.89 |
|
Sales Per Share
|
9.98 |
|
EBITDA (p.s.)
|
-5.63 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-262 (M) |
|
Levered Free Cash Flow
|
110 (M) |
Stock Valuations |
|
PE Ratio
|
-17.97 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
13.3 |
|
Price to Sales
|
12.8 |
|
Price to Cash Flow
|
-42.76 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
